greater than or equal to 2X nadir value for patients with an elevated pre-treatment CA125 that never normalizes). 4. Gynecological Oncology Group performance status of 0 or 1 5. Life expectancy greater than or equal to 3 months 6. Patients must have recovered from effects of any major surgery within 28 days from the first dose of study treatment. 7. Adequate hematologic, renal, liver, and coagulation system function as defined by laboratory values performed within 21 days prior to initiation of dosing. [clinicaltrials_resource:85a168d104680cad19f0a2c80b85869c]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
greater than or equal to 2X nadir value for patients with an elevated pre-treatment CA125 that never normalizes). 4. Gynecological Oncology Group performance status of 0 or 1 5. Life expectancy greater than or equal to 3 months 6. Patients must have recovered from effects of any major surgery within 28 days from the first dose of study treatment. 7. Adequate hematologic, renal, liver, and coagulation system function as defined by laboratory values performed within 21 days prior to initiation of dosing. [clinicaltrials_resource:85a168d104680cad19f0a2c80b85869c]
Bio2RDF identifier
85a168d104680cad19f0a2c80b85869c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:85a168d104680cad19f0a2c80b85869c
identifier
clinicaltrials_resource:85a168d104680cad19f0a2c80b85869c
title
greater than or equal to 2X na ...... prior to initiation of dosing.
@en
type
label
greater than or equal to 2X na ...... 168d104680cad19f0a2c80b85869c]
@en